[Pharmaceutical care for patients and their caregivers in Alzheimer's disease and related disorders: a review and new perspectives].
Identifieur interne : 000358 ( Main/Exploration ); précédent : 000357; suivant : 000359[Pharmaceutical care for patients and their caregivers in Alzheimer's disease and related disorders: a review and new perspectives].
Auteurs : Teddy Novais [France] ; Christelle Mouchoux [France]Source :
- Geriatrie et psychologie neuropsychiatrie du vieillissement [ 2115-7863 ] ; 2019.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Aidants (MeSH), Femelle (MeSH), Humains (MeSH), Maladie d'Alzheimer (psychologie), Maladie d'Alzheimer (traitement médicamenteux), Mâle (MeSH), Pharmaciens (MeSH), Qualité de vie (MeSH), Services pharmaceutiques (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH).
- MESH :
- psychologie : Maladie d'Alzheimer.
- traitement médicamenteux : Maladie d'Alzheimer.
- Adulte d'âge moyen, Aidants, Femelle, Humains, Mâle, Pharmaciens, Qualité de vie, Services pharmaceutiques, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- MESH :
- drug therapy : Alzheimer Disease.
- psychology : Alzheimer Disease.
- Aged, Aged, 80 and over, Caregivers, Female, Humans, Male, Middle Aged, Pharmaceutical Services, Pharmacists, Quality of Life.
Abstract
Many arguments support the development of pharmaceutical care in patients with neurocognitive disorders and their caregivers: polypharmacy, drug-related cognitive decline, poor drug adherence, increased use of psychotropic drugs and potentially inappropriate medications. The aim of this narrative review was to identify the pharmacist's roles in caring for patients with Alzheimer's disease and related disorders and their caregivers. Seventeen publications were selected after literature research. The various interventions conducted by pharmacists were as follows: achievement of a medication review that could be focused on the reduction of the anticholinergic burden or the number of psychotropic drugs, therapeutic education of the patient and his caregiver concerning the treatment management, personalized pharmaceutical follow-up, screening and orientation of patients with a cognitive impairment or caregivers with signs of fragility (burden, anxiety or depressive symptoms). The majority of studies targeted the patient care. Other interventional studies will be necessary to evaluate the impact of a pharmaceutical care for the dyad, including the caregiver, on the improvement of drug management but also on clinical outcomes, including the cognitive function, the autonomy, the use of the health care system, the quality of life and the self-efficacy.
DOI: 10.1684/pnv.2018.0767
PubMed: 30907370
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Pharmaceutical care for patients and their caregivers in Alzheimer's disease and related disorders: a review and new perspectives].</title><author><name sortKey="Novais, Teddy" sort="Novais, Teddy" uniqKey="Novais T" first="Teddy" last="Novais">Teddy Novais</name><affiliation wicri:level="3"><nlm:affiliation>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, EA 7425 Health Services and Performance Research, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, EA 7425 Health Services and Performance Research, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Mouchoux, Christelle" sort="Mouchoux, Christelle" uniqKey="Mouchoux C" first="Christelle" last="Mouchoux">Christelle Mouchoux</name><affiliation wicri:level="3"><nlm:affiliation>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, Inserm U1028, CNRS UMR5292, Centre de recherche en neuroscience, Équipe DYCOG, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, Inserm U1028, CNRS UMR5292, Centre de recherche en neuroscience, Équipe DYCOG, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30907370</idno><idno type="pmid">30907370</idno><idno type="doi">10.1684/pnv.2018.0767</idno><idno type="wicri:Area/Main/Corpus">000542</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000542</idno><idno type="wicri:Area/Main/Curation">000542</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000542</idno><idno type="wicri:Area/Main/Exploration">000542</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Pharmaceutical care for patients and their caregivers in Alzheimer's disease and related disorders: a review and new perspectives].</title><author><name sortKey="Novais, Teddy" sort="Novais, Teddy" uniqKey="Novais T" first="Teddy" last="Novais">Teddy Novais</name><affiliation wicri:level="3"><nlm:affiliation>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, EA 7425 Health Services and Performance Research, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, EA 7425 Health Services and Performance Research, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Mouchoux, Christelle" sort="Mouchoux, Christelle" uniqKey="Mouchoux C" first="Christelle" last="Mouchoux">Christelle Mouchoux</name><affiliation wicri:level="3"><nlm:affiliation>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, Inserm U1028, CNRS UMR5292, Centre de recherche en neuroscience, Équipe DYCOG, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, Inserm U1028, CNRS UMR5292, Centre de recherche en neuroscience, Équipe DYCOG, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author></analytic><series><title level="j">Geriatrie et psychologie neuropsychiatrie du vieillissement</title><idno type="eISSN">2115-7863</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Alzheimer Disease (drug therapy)</term><term>Alzheimer Disease (psychology)</term><term>Caregivers (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pharmaceutical Services (MeSH)</term><term>Pharmacists (MeSH)</term><term>Quality of Life (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Aidants (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Maladie d'Alzheimer (psychologie)</term><term>Maladie d'Alzheimer (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Pharmaciens (MeSH)</term><term>Qualité de vie (MeSH)</term><term>Services pharmaceutiques (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Alzheimer Disease</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Maladie d'Alzheimer</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Alzheimer Disease</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie d'Alzheimer</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Caregivers</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pharmaceutical Services</term><term>Pharmacists</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Aidants</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Pharmaciens</term><term>Qualité de vie</term><term>Services pharmaceutiques</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many arguments support the development of pharmaceutical care in patients with neurocognitive disorders and their caregivers: polypharmacy, drug-related cognitive decline, poor drug adherence, increased use of psychotropic drugs and potentially inappropriate medications. The aim of this narrative review was to identify the pharmacist's roles in caring for patients with Alzheimer's disease and related disorders and their caregivers. Seventeen publications were selected after literature research. The various interventions conducted by pharmacists were as follows: achievement of a medication review that could be focused on the reduction of the anticholinergic burden or the number of psychotropic drugs, therapeutic education of the patient and his caregiver concerning the treatment management, personalized pharmaceutical follow-up, screening and orientation of patients with a cognitive impairment or caregivers with signs of fragility (burden, anxiety or depressive symptoms). The majority of studies targeted the patient care. Other interventional studies will be necessary to evaluate the impact of a pharmaceutical care for the dyad, including the caregiver, on the improvement of drug management but also on clinical outcomes, including the cognitive function, the autonomy, the use of the health care system, the quality of life and the self-efficacy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30907370</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2115-7863</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>03</Month><Day>01</Day></PubDate></JournalIssue><Title>Geriatrie et psychologie neuropsychiatrie du vieillissement</Title><ISOAbbreviation>Geriatr Psychol Neuropsychiatr Vieil</ISOAbbreviation></Journal><ArticleTitle>[Pharmaceutical care for patients and their caregivers in Alzheimer's disease and related disorders: a review and new perspectives].</ArticleTitle><Pagination><MedlinePgn>7-19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1684/pnv.2018.0767</ELocationID><Abstract><AbstractText>Many arguments support the development of pharmaceutical care in patients with neurocognitive disorders and their caregivers: polypharmacy, drug-related cognitive decline, poor drug adherence, increased use of psychotropic drugs and potentially inappropriate medications. The aim of this narrative review was to identify the pharmacist's roles in caring for patients with Alzheimer's disease and related disorders and their caregivers. Seventeen publications were selected after literature research. The various interventions conducted by pharmacists were as follows: achievement of a medication review that could be focused on the reduction of the anticholinergic burden or the number of psychotropic drugs, therapeutic education of the patient and his caregiver concerning the treatment management, personalized pharmaceutical follow-up, screening and orientation of patients with a cognitive impairment or caregivers with signs of fragility (burden, anxiety or depressive symptoms). The majority of studies targeted the patient care. Other interventional studies will be necessary to evaluate the impact of a pharmaceutical care for the dyad, including the caregiver, on the improvement of drug management but also on clinical outcomes, including the cognitive function, the autonomy, the use of the health care system, the quality of life and the self-efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Novais</LastName><ForeName>Teddy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, EA 7425 Health Services and Performance Research, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouchoux</LastName><ForeName>Christelle</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Secteur pharmaceutique, Hôpital des Charpennes, Institut du vieillissement, Hospices civils de Lyon, Villeurbanne, France, Inserm U1028, CNRS UMR5292, Centre de recherche en neuroscience, Équipe DYCOG, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Rôle du pharmacien dans la prise en soin de la dyade patient/aidant dans la maladie d’Alzheimer et les maladies apparentées : revue de la littérature et nouvelles perspectives.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Geriatr Psychol Neuropsychiatr Vieil</MedlineTA><NlmUniqueID>101553404</NlmUniqueID><ISSNLinking>2115-7863</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="Y">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010593" MajorTopicYN="Y">Pharmaceutical Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010595" MajorTopicYN="Y">Pharmacists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Alzheimer's disease</Keyword><Keyword MajorTopicYN="Y">caregiver</Keyword><Keyword MajorTopicYN="Y">pharmaceutical care</Keyword><Keyword MajorTopicYN="Y">pharmacist</Keyword><Keyword MajorTopicYN="Y">review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30907370</ArticleId><ArticleId IdType="pii">pnv.2018.0767</ArticleId><ArticleId IdType="doi">10.1684/pnv.2018.0767</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Novais, Teddy" sort="Novais, Teddy" uniqKey="Novais T" first="Teddy" last="Novais">Teddy Novais</name></region><name sortKey="Mouchoux, Christelle" sort="Mouchoux, Christelle" uniqKey="Mouchoux C" first="Christelle" last="Mouchoux">Christelle Mouchoux</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000358 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000358 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30907370
|texte= [Pharmaceutical care for patients and their caregivers in Alzheimer's disease and related disorders: a review and new perspectives].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30907370" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |